• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.

作者信息

Fillon Mike

出版信息

CA Cancer J Clin. 2018 May;68(3):178-179. doi: 10.3322/caac.21423. Epub 2018 Mar 25.

DOI:10.3322/caac.21423
PMID:29574786
Abstract
摘要

相似文献

1
Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.免疫检查点抑制剂作为非小细胞肺癌患者的二线治疗方案优于多西他赛。
CA Cancer J Clin. 2018 May;68(3):178-179. doi: 10.3322/caac.21423. Epub 2018 Mar 25.
2
Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.免疫检查点抑制剂在台湾作为二线治疗非小细胞肺癌的成本效益分析。
Future Oncol. 2022 Mar;18(7):859-870. doi: 10.2217/fon-2021-0785. Epub 2022 Feb 2.
3
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.接受检查点抑制剂治疗的晚期非小细胞肺癌患者的生存相关临床和分子特征：系统评价和荟萃分析。
JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427.
4
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.多西他赛联合巴维昔单抗治疗既往治疗的晚期非鳞状非小细胞肺癌的随机 III 期研究。
Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.
5
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.免疫检查点抑制剂在晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性：一项系统文献综述。
Oncoimmunology. 2020 Jun 16;9(1):1774314. doi: 10.1080/2162402X.2020.1774314.
6
Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition.二线晚期非小细胞肺癌的显著进展：检查点抑制的快速发展领域。
J Clin Oncol. 2016 May 10;34(14):1676-88. doi: 10.1200/JCO.2015.63.8049. Epub 2016 Feb 16.
7
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.《转移性 EGFR 突变非小细胞肺癌中免疫检查点抑制剂的Meta 分析》
J Thorac Oncol. 2017 Feb;12(2):403-407. doi: 10.1016/j.jtho.2016.10.007. Epub 2016 Oct 17.
8
Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.纳武利尤单抗治疗后序贯多西他赛 +/- 雷莫芦单抗和 S-1 方案治疗晚期非小细胞肺癌患者的疗效。
Thorac Cancer. 2019 May;10(5):1141-1148. doi: 10.1111/1759-7714.13055. Epub 2019 Mar 26.
9
Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.晚期非小细胞肺癌患者的免疫检查点抑制剂：一项系统评价
Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. doi: 10.1016/j.cllc.2017.02.001. Epub 2017 Feb 16.
10
[Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer].多西他赛联合PD-1/PD-L1抑制剂用于晚期非小细胞肺癌二线治疗的临床分析
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):605-612. doi: 10.3779/j.issn.1009-3419.2021.102.26. Epub 2021 Aug 30.

引用本文的文献

1
MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma.基质金属蛋白酶11与表皮生长因子受体（EGFR）突变型肺腺癌的免疫反应和免疫微环境相关。
Front Oncol. 2023 Jan 23;13:1055122. doi: 10.3389/fonc.2023.1055122. eCollection 2023.
2
Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell.利用自然杀伤细胞提高肿瘤治疗策略概述。
J Immunol Res. 2020 Jan 21;2020:8459496. doi: 10.1155/2020/8459496. eCollection 2020.
3
Efficacy of EGFR-TKIs with or without angiogenesis inhibitors in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
表皮生长因子受体酪氨酸激酶抑制剂联合或不联合血管生成抑制剂治疗晚期非小细胞肺癌的疗效：一项系统评价与荟萃分析。
J Cancer. 2020 Jan 1;11(3):686-695. doi: 10.7150/jca.34957. eCollection 2020.
4
Suicide among cancer patients: adolescents and young adult (AYA) versus all-age patients.癌症患者中的自杀：青少年和青年（AYA）与所有年龄段患者的对比。
Ann Transl Med. 2019 Nov;7(22):658. doi: 10.21037/atm.2019.10.51.
5
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.免疫检查点抑制剂联合化疗与免疫治疗晚期非小细胞肺癌的比较：系统评价和荟萃分析。
J Cell Physiol. 2020 May;235(5):4913-4927. doi: 10.1002/jcp.29371. Epub 2019 Nov 6.
6
miR-134-5p Promotes Stage I Lung Adenocarcinoma Metastasis and Chemoresistance by Targeting DAB2.miR-134-5p通过靶向DAB2促进I期肺腺癌转移和化疗耐药。
Mol Ther Nucleic Acids. 2019 Dec 6;18:627-637. doi: 10.1016/j.omtn.2019.09.025. Epub 2019 Oct 3.
7
The construction and analysis of the aberrant lncRNA-miRNA-mRNA network in non-small cell lung cancer.非小细胞肺癌中异常lncRNA-miRNA-mRNA网络的构建与分析
J Thorac Dis. 2019 May;11(5):1772-1778. doi: 10.21037/jtd.2019.05.69.